{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:41Z","timestamp":1791915881476,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair follicles characterized by recurrent, painful nodules, abscesses, and sinus tracts (\u201ctunnels\u201d) typically refractory to treatment. This debilitating condition results in poor quality of life due to high disease burden. Intralesional triamcinolone (ILTAC) is a standard of care for acute inflammation and drainage associated with HS; however, the optimal therapeutic dose has not been determined. We investigated the utility of high\u2010dose ILTAC 20\u00a0mg\/ml (ILTAC\u201020) or 40\u00a0mg\/ml (ILTAC\u201040), for inflammatory lesions of HS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review and telephone questionnaire included HS patients treated with high\u2010dose ILTAC\u201020 or ILTAC\u201040 between April and December 2018. Patients with Hurley stages I\u2013III were included. Data were obtained from electronic medical records and telephone interviews. A short questionnaire pertained to satisfaction with therapy, changes of disease state, and modifications in quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 54 patients interviewed, the average age was 36.9\u00a0\u00b1\u00a011.6\u00a0years; 36 (66.7%) were female. Forty patients (76.9%) were very satisfied (<jats:italic>n<\/jats:italic>\u00a0=\u00a019) or satisfied (<jats:italic>n<\/jats:italic>\u00a0=\u00a021) with high\u2010dose ILTAC therapy. Fifty patients (92.6%) demonstrated improvements in disease state, and 41 patients (75.9%) experienced enhanced quality of life. Forty\u2010four patients (86.3%) were amenable to additional injections of high\u2010dose ILTAC, if clinically indicated. No adverse effects of therapy were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The majority of patients reported improvements in disease state, quality of life, and overall satisfaction after administration of high\u2010dose ILTAC (20\u201340\u00a0mg\/ml). These findings support the use of high\u2010dose ILTAC for acute lesions of HS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.15124","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:35:15Z","timestamp":1598618115000},"page":"217-221","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy of high\u2010dose intralesional triamcinolone for hidradenitis suppurativa"],"prefix":"10.1111","volume":"60","author":[{"given":"Jessica","family":"Garelik","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Babbush","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-1997","authenticated-orcid":false,"given":"Mondana","family":"Ghias","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1014163"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11337.1"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2450401"},{"key":"e_1_2_5_5_1","unstructured":"PacificKP BabbushKM JohnstonA et al.Erythrocyte Sedimentation rate C\u2010Reactive Protein Interleukin\u20106 and Tumor Necrosis Factor Alpha Levels Predict Hidradenitis Suppurativa Severity. 4th Annual Symposium on Hidradenitis Suppurativa Advances; November2019; Detroit MI."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2017.65626"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2014.07.012"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.08.020"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499934"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.049"},{"key":"e_1_2_5_12_1","unstructured":"Information NCfB.Triamcinolone CID=31307. Accessed November 19 2019."},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002112"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0b013e3181df0f3b"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0201"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000453355"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0759"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-017-0647-3"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)70017-3"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T19:10:32Z","timestamp":1693422632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/ijd.15124"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15124","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"2020-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}